Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis

Hematogenous Candida meningoencephalitis (HCME) is a life-threatening complication of neonates and immunocompromised children. Amphotericin B (AmB) shows poor permeation and low cerebrospinal fluid (CSF) concentrations but is effective in the treatment of HCME. In order to better understand the mechanism of CNS penetration of AmB, we hypothesized that AmB may achieve focally higher concentrations in infected CNS lesions. ABSTRACT Hematogenous Candida meningoencephalitis (HCME) is a life-threatening complication of neonates and immunocompromised children. Amphotericin B (AmB) shows poor permeation and low cerebrospinal fluid (CSF) concentrations but is effective in the treatment of HCME. In order to better understand the mechanism of CNS penetration of AmB, we hypothesized that AmB may achieve focally higher concentrations in infected CNS lesions. An in vitro blood-brain barrier (BBB) model was serially infected with Candida albicans. Liposomal AmB (LAMB) or deoxycholate AmB (DAMB) at 5 μg/ml was then provided, and the vascular and CNS compartments were sampled 4 h later. For in vivo correlation, rabbits with experimental HCME received a single dose of DAMB at 1 mg/kg of body weight or LAMB at 5 mg/kg and were euthanized after 1, 3, 6, and 24 h. Evans blue dye solution (2%, 2 ml/kg) administered intravenously (i.v.) at 1 h prior to euthanasia stained infected regions of tissue but not histologically normal areas. AmB concentrations in stained and unstained tissue regions were measured using ultraperformance liquid chromatography. For selected rabbits, magnetic resonance imaging (MRI) scans performed on days 1 to 7 postinoculation were acquired before and after i.v. bolus administration of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) at 15-min intervals through 2 h postinjection. The greatest degree of penetration of DAMB and LAMB through the in vitro BBB occurred after 24 h of exposure (P = 0.0022). In vivo the concentrations of LAMB and DAMB in brain abscesses were 4.35 ± 0.59 and 3.14 ± 0.89 times higher, respectively, than those in normal tissue (P ≤ 0.019). MRI scans demonstrated that Gd-DTPA accumulated in infected areas with a disrupted BBB. Localized BBB disruption in HCME allows high concentrations of AmB within infected tissues, despite the presence of low cerebrospinal fluid concentrations.

[1]  T. Walsh,et al.  Invasive Candidiasis in Infants and Children: Recent Advances in Epidemiology, Diagnosis, and Treatment , 2019, Journal of fungi.

[2]  F. Vilar,et al.  Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections , 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[3]  H. Badali,et al.  Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates , 2017, BMC Infectious Diseases.

[4]  T. Walsh,et al.  Drugs currently under investigation for the treatment of invasive candidiasis , 2017, Expert opinion on investigational drugs.

[5]  J. Perfect The antifungal pipeline: a reality check , 2017, Nature Reviews Drug Discovery.

[6]  J. Perfect,et al.  Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis , 2017, Antimicrobial Agents and Chemotherapy.

[7]  M. Finkelman,et al.  (1→3)-β-d-Glucan in Cerebrospinal Fluid as a Biomarker for Candida and Aspergillus Infections of the Central Nervous System in Pediatric Patients. , 2016, Journal of the Pediatric Infectious Diseases Society.

[8]  N. Frede,et al.  Successful Granulocyte Colony-stimulating Factor Treatment of Relapsing Candida albicans Meningoencephalitis Caused by CARD9 Deficiency. , 2016, The Pediatric infectious disease journal.

[9]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[11]  A. Schäffer,et al.  Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. , 2015, The Journal of allergy and clinical immunology.

[12]  A. Rosengart,et al.  Mold infections of the central nervous system. , 2014, The New England journal of medicine.

[13]  M. Walsh,et al.  Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. , 2013, The Journal of pediatrics.

[14]  J. Perfect,et al.  Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints , 2013, Antimicrobial Agents and Chemotherapy.

[15]  Udo Albus,et al.  Book Review: Guide for the Care and use of Laboratory Animals , 1998 .

[16]  D. Stevens,et al.  Experimental Central Nervous System Aspergillosis Therapy: Efficacy, Drug Levels and Localization, Immunohistopathology, and Toxicity , 2012, Antimicrobial Agents and Chemotherapy.

[17]  H. Ibrahim,et al.  In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. , 2011, Journal of medical microbiology.

[18]  T. Walsh,et al.  Effects of Immunomodulatory and Organism-Associated Molecules on the Permeability of an In Vitro Blood-Brain Barrier Model to Amphotericin B and Fluconazole , 2009, Antimicrobial Agents and Chemotherapy.

[19]  Maria R R Silva,et al.  Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV+ patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates , 2009, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[20]  Maria R R Silva,et al.  Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV+ patients to fluconazole, amphotericin B and Caspofungin: killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates , 2009 .

[21]  T. Walsh,et al.  Cerebrospinal Fluid and Plasma (1→3)-β-d-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous Candida Meningoencephalitis , 2008, Antimicrobial Agents and Chemotherapy.

[22]  G. Drusano,et al.  The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. , 2008, The Journal of infectious diseases.

[23]  William Oh,et al.  Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2006, Pediatrics.

[24]  T. Walsh,et al.  Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. , 2003, Pediatrics.

[25]  J. McCullers,et al.  Candidal meningitis in children with cancer. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  S. Piscitelli,et al.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. , 2000, The Journal of infectious diseases.

[27]  T. Walsh,et al.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. , 1988, Laboratory animal science.

[28]  F. Balis,et al.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. , 1988, The Journal of infectious diseases.

[29]  M. Ghannoum,et al.  Correlative relationship between proteinase production, adherence and pathogenicity of various strains of Candida albicans. , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[30]  J. Church,et al.  Case Report: Primary Candida Meningitis Chronic Granulomatous Disease , 1986 .

[31]  J. Church,et al.  Primary Candida meningitis and chronic granulomatous disease. , 1986, The American journal of the medical sciences.

[32]  D. Alexander,et al.  The National Institute of Child Health and Human Development , 1965, Nature.